SEARCH · Search PubMed

Results for “ANTIVENINS”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

SourceResearch connectionFrom yearThrough year

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 73 records · Page 4Linked to original sources

PubMed2003

Serum sickness following administration of Antivenin (Crotalidae) Polyvalent in 181 cases of presumed rattlesnake envenomation.

OBJECTIVE: To describe the incidence and characteristics of serum sickness (SS) following administration of Wyeth Antivenin (Crotalidae) Polyvalent (ACP). METHODS: A retrospective chart review was conducted involving presumed rattlesnake bite victims referred to our poison center. Serum sickness was defined as unexplained rash developing 3 to 21 days following the administration of ACP. Patients were monitored until complete resolution of all symptoms. Data collected included total number of ACP vials administered, associated signs and symptoms, duration of signs and symptoms, and medications used to treat SS. RESULTS: Of the 181 cases included in our study, SS occurred in 102 (56%) patients. The frequency of SS in patients receiving fewer than 20, 20 to 29, 30 to 39, or 40 or more vials was 34%, 36%, 88%, and 100%, respectively. Duration of SS averaged 6.1 days (range, 1-21 days). Associated symptoms included subjective fever (49%), arthralgia (20%), and pruritus (40%). Reported medications used included prednisone (98%), antihistamines (92%), and histamine-2 blockers (3%). CONCLUSIONS: Serum sickness following administration of Wyeth ACP is common, with a strong correlation between ACP dosage and SS frequency.

Animals↗

PubMed1996

Heterologous antisera and antivenins are essential biologicals: perspectives on a worldwide crisis.

Active immunization against infectious disease is important. However, much of our world faces poverty, social injustice, and warfare, all of which cause universal immunization to remain a distant dream. Agents that provide passive immunity thus remain essential biologicals. The most important of these are human or equine antisera against rabies, tetanus, diphtheria, and snake antivenins. Homologous products are either unavailable or unaffordable in places where they are needed the most. Less expensive heterologous (equine) antisera can be purified and are safe to use, but these antisera are also in short supply. Monoclonal antibodies have been developed but are even less likely to be affordable in poor countries. Several traditional sources of equine antisera are becoming depleted as a result of economic disincentives; a poor reputation based on the high adverse reaction rates of the old, unpurified products; and the activities of animal rights activists who object to the use of horses as blood donors. Purified, pepsin-digested equine antisera are preferred; but developing countries sometimes are forced to make crude products that are less safe or have no specific therapy available at all.

Antivenins↗

PubMed1979

Production of potent antivenin against cobra venom with conjugated-cobrotoxin.

Cobra venom (Naja naja atra) and its fractions obtained by ammonium sulfate precipitation were subjected to chromatography on CM-Cellulose colum. A highly purified cobrotoxin obtained by the repeated chromatography on preparative CM-Cellulose column was 6.7 times more toxic than the original cobra venom. The toxin was detoxified by a bifunctional reagent, glutaraldehyde, to about 99.8% and utilized for immunization in animals. Mice received 4 weekly immunization with detoxified cobrotoxin and challenged one week after the last injection showed 60% protection in rabbits by immunization with detoxified cobrotoxin reached 360 LD50 neutralizing level against the cobra venom within 30 days. The results indicate that it is feasible and promising to prepare potent antivenin in animals by glutaraldehyde-treated cobrotoxin.

Adjuvants, Immunologic↗

PubMed2002

[Comparative titration of three antivenin serums used against sub-Saharan African snakes].

The standardisation of serotherapy is necessary in Africa mainly because of the frequency of envenomations and the lack of alternative treatments. Comparative titrations of FAV-Afrique (Aventis Pasteur), Polyvalent serum (Serum Institute of India = SII) and Polyvalent antivenin (South African Vaccine Fabricants Ltd = SAIMR) were carried out on venoms of Echis ocellatus from Cameroun, E. ocellatus from Mali, E. leucogaster and Naja melanoleuca. The 50% protective doses (ED50) of the antivenoms were given according either to i) the in vitro method which consists of inoculating 5 batches of 5 mice with a mixture containing 3 DL50 of venom and increasing volumes of antivenom incubated for 30 mn at 37 degrees C and ii) the in vivo method which consists of successive administration of venom and then antivenom after a 30 to 60 mn interval. The three antivenoms showed a similar efficacy against all the Echis venoms. Interestingly, the SAIMR proved to be effective against the venom of E. leucogaster and E. ocellatus although no venom of Echis was used to immunise horses during the preparation of antivenom. Conversely, this paraspecificity did not exist with the Naja melanoleuca venom against which FAV Afrique showed a higher efficacy. The electrophoresis pattern of FAV-Afrique performed on acetate gel strips showed only one protein fraction (76 g.l-1), whereas both the SII and SAIMR antivenoms showed four fractions whose protein concentrations was respectively 64 g.l-1 and 145 g.l-1.

Africa South of the Sahara↗

PubMed2005

An unusual localization of snakebite treated without antivenin: case report.

Snakebite is one of the commonest causes of morbidity and mortality in tropical regions. This paper focuses on the medical treatment of a patient who had been bitten by a snake on the vertex of his head. It was a severe envenomation with ensuing marked edema associated with coagulation abnormalities. Although the antivenin was extensively sought in various medical centers, it was unavailable. We observed and treated the patient, with special regard to his hematological findings and potential complications. Specifically, tetanus prophylaxis and intravenous fluids were administered, and the wound was cleaned and dressed. Fresh frozen plasma was also administered. The patient responded well, and was discharged on the fourth day of his admission, without any sequelae.

Adolescent↗

PubMed1982

Enhancement of Naja naja atra antivenin production in horses.

As the conventional hyperimmunization schedule in horses introduced by Tanaka could not produce enough neutralizing antibody against Naja naja atra venom, the mixture of Carboxymethyl cellulose (CMC)-Cobra venom incorporated with adjuvant was used for immunization. The neutralizing antibody produced (30 LD50) seemed to be increased but still not to reach the satisfactory level. By using CMC-Cobratoxin adjuvant mixture as an immunizing agent, highly potent antivenin (220 LD50) was obtained.

Adjuvants, Immunologic↗

PubMed1997

Therapeutic experience of venomous snakebites by the Japanese viper (Agkistrodon halys Blomhoffii) with low dose of antivenin: report of 43 consecutive cases.

Forty-three consecutive patients of venomous snakebite by the Japanese viper (Agkistrodon halys Blomhoffii, "Mamushi" in Japanese) were treated with an uniformly scheduled therapy from 1990 and 1994. The therapy was mainly composed of minimal dose of antivenin, methylprednisolon and cepharanthin. There were two clinical courses, i.e., the minimal envenomation course (Group A, n = 14) and the severe one (Group B, n = 29). Our treatment was so satisfactory that all patients of both groups fully recovered activities of daily living with neither organic disorders nor sequelae of the bitten extremities. The high appearance ratio of atypical lymphocytes (P < 0.05) and the increased ratio of lymphocyte count to White blood cell count (P < 0.02) could be indicators that predict which clinical courses the patients take.

Adolescent↗

PubMed1964